Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)
Vanderbilt-Ingram Cancer Center
Vanderbilt-Ingram Cancer Center
M.D. Anderson Cancer Center
Case Comprehensive Cancer Center
Memgen, Inc.
DEKA Biosciences
Ikena Oncology
Fate Therapeutics
Fate Therapeutics
Celgene
Five Prime Therapeutics, Inc.